MAbs, such as Infliximab and Adalimumab, which directly neutralize TNF-α, are extensively utilized in the treatment of autoimmune disorders, including inflammatory bowel disease and rheumatoid arthritis [122,123]. This evidence concerns the gene TNF and rheumatoid arthritis.